In the specialized field of biochemical research, the study of synthetic sequences has opened doors to understanding complex cellular signaling pathways. As an enthusiast who follows the latest developments in molecular biology, I have spent considerable time reviewing literature regarding the emp 1 peptide. This compound, often discussed in the contex This peptide is a mimetic of erythropoietin. Johnson DL, et al., Biochemistry, 37, 3699 (1998). M.W.: 2093.39. Related products. Placeholder. t of its role as a mimetic of erythropoietin, represents a fascinating intersection of structural biology and receptor interaction studies.
Understanding the Molecular Profile of EMP-1
When analyzing Erythropoietin-Mimetic Peptide 1 (EMP-1), it is essential to distinguish it from the endogenous glycoprotein. The structural uniqueness of this peptide lies in its consensus sequence (YXCXXGPXTWXCXP), which allows it to interact specifically with the erythropoietin receptor. Researchers have noted that EMP-1 functions as a homodimer, a critical configuration that facilitates the activation of the receptor's extracellular domain.
From a technical standpoint, the molecular weight of this substance is approximately 2093.39 Daltons. My observation of various laboratory reports indicates that this 1 sequ emp BIOTECH's ence is a subject of significant interest due to its ability to compete with natural ligands. It is important to note that EPO mimetic peptide-1 (EMP1) has been studied for its effects on cell p EPO mimetic peptide-1 (EMP-1) | CAS 186526-28-3 roliferation and its influence on the cell cycle, particularly in controlled *in vitro* environments.
Distinctions in Nomenclature: EMP-1 vs. Epithelial Membrane Protein 1
A common point of confusion in literature is the overlap in naming conventions. While some contexts refer to Epithelial membrane protein 1 (EMP1)—a protein encoded by the *EMP1* gene—this should not be conflated with the synthetic EPO mimetic peptide-1 (EMP-1). The former is a glycoprotein that is highly expressed in brain tumor cells and serves as a multifunctional regulator, whereas the latter is a synthetic metic peptide sequence design Restrain of Bone Growth by Estrogen-Mimetic peptide-1 ed for specific receptor-binding research. Clarifying this distinction is vital for anyone tracking the specific properties of Epithelial membrane protein 1.
Scientific Observations and Research Applications
In experimental settings, the peptide EMP-1 restrains bone growth in specific animal models, a finding that highlights the diverse biological pathways that can be modulated by small synthetic molecules. Furthermore, the Erythropoietin-Mimetic Peptide 17 (EMP17) is frequently discussed alongside EMP-1. EMP17 is another derivative that activates the receptor, and it is known that the two potentially reactive am The crystal structure of EMP-1 and a recombinant soluble EPOR complex [59] demonstrated that EMP-1 functions as a homodimer, and involves two EMP-1 molecules ines present in its structure—one at the N-terminus and one in the lysine side chain—are critical for its chemical stability and labeling, such as with FITC for visualization.
Important Considerations for Research Integrity
For those interested in the history of these compounds, it is well-documented that Erythropoietin (EPO) mimetic peptide (EMP) was initially identified to explore the potential of non-proteinaceous agonists. While the research is robust, it is essential to emphasize that these compounds are strictly for laboratory and analytical use.
There has been discourse regarding the misuse of these substances, specifically that the linear form of EMP1 is a performance-enhancing doping agent prohibited in various sporting contexts. Furthermore, while EPO-5, a short synthetic peptide fragment, and similar p54849 · emp1_human sequences like EMP-1 are studied for their potential to stimulate erythroid colony formation, they are far removed from clinical applications. Scientific literature notes that while they can correct anemia in patients with pure red-cell aplasia in experimental or theoretical models involving anti-erythropoietin antibodies, these are highly controlled investigative scenarios.
Summary of Key Entities
* EMP-1: A 20-amino acid synthetic peptide acting as an EPO receptor agonist.
* Erythropoietin: The prima One EPO mimetic peptide sequence, EMP1, was targeted and more than 25 derivatives of this sequence were evaluated for their ability to compete with [125I]EPO ry hormone involved in red bloo Epithelial membrane protein 1 is a protein that in humans is encoded by the EMP1 gene. EMP1. Identifiers. Aliases · EMP1, CL-20, EMP-1, TMP, d cell production.
* EMP1 (Gene): A regulator of cell-cell interactions, distinct from the synthetic peptide.
* Research Focus: Investigatin Identification of erythropoietin mimetic peptide 1 linear form in g binding affinity, homodimerization, and receptor activation.
Whether you are looking at the solubility profiles or the way plasma contains over 120 different proteins that interact within complex systems, the study of these peptides requires a high degree of precision. The peptide must always be stored according to manufacturer guidelines—usually in a lyophilized state at 0–5°C—to ensure it exhibits correct molecular weight and structural integrity for any valid scientific inquiry. Always ensure that your research aligns with institutional guidelines and ethical standards regarding the use of bioactive synthetic compounds.